- Home
- NMM vs AUPH Comparison
NMM vs AUPH Comparison
Compare NMM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMM | AUPH |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2007 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NMM | AUPH |
|---|---|---|
| Price | $51.31 | $15.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 120.7K | ★ 1.6M |
| Earning Date | 11-18-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.91 | 0.55 |
| Revenue | ★ $1,311,114,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.22 |
| Revenue Next Year | $15.22 | $15.40 |
| P/E Ratio | ★ $5.78 | $28.81 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $28.37 | $6.55 |
| 52 Week High | $56.44 | $16.48 |
Technical Indicators
Market Signals| Indicator | NMM | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 59.93 |
| Support Level | $54.62 | $15.15 |
| Resistance Level | $56.19 | $16.03 |
| Average True Range (ATR) | 1.35 | 0.50 |
| MACD | -0.56 | -0.13 |
| Stochastic Oscillator | 6.43 | 64.33 |
Price Performance
Historical ComparisonAbout NMM Navios Maritime Partners LP
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.